Entity

Time filter

Source Type

QLT
Vancouver, Canada

Patent
Qlt | Date: 2012-06-26

A punctal plug for insertion through a punctal aperture of an eye. The punctal plug includes a stem configured to be inserted into the punctal aperture and along a canaliculus of the eye, a stopper connected to one end of the stem, the stopper configured to seat against the punctal aperture, and a topical prostaglandin. The stem and the stopper are made from a porous or absorbent material, and wherein the material is saturated with the topical prostaglandin.


Surface treated implantable articles and related methods are disclosed. The surface treated implantable articles can be substantially flash-free, include one or more rounded edges, or include an enhanced optical clarity, one or all of which can be produced by polishing. The polishing can include causing the implantable articles to be repeatedly impacted with polishing media when the articles are swelled to an enlarged state. The polishing process can be particularly useful for smoothing lacrimal implants insertable in a lacrimal canaliculus.


A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through an upper punctum and into an upper lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a lower punctum and into a lower lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.


Therapeutic regimes for improving visual function in a subject having a deficiency in endogenously produced 11-cis retinal comprising administering the synthetic retinal derivative as a divided dose over 2-7 days then providing a resting period of 7-28 days after which the second dose of the synthetic retinal derivative is administered. Preferred synthetic retinal derivatives are 9- or 11-cis-retinyl esters. Disorders associated with deficiency in endogenously produced 11-cis retinal include retinitis pigmentosa and Leber congenital amaurosis.


Patent
Qlt | Date: 2012-04-16

The present invention describes an improved photodynamic treatment to treat subfoveal choroidal neovascularization (CNV).

Discover hidden collaborations